- RBI extends implementation of card tokenisation norms by 3 months; deadline extended till 30 September
- EXCLUSIVE: 'Noida International Airport at Jewar to be jewel in crown of Indian aviation sector' - Know what all is coming up at
- D-Street Corner: Market gains 2.7% in highly volatile week, investors richer by 5.5 lakh cr; what should investors do on Monday?
- Sebi allows UPI payment option to invest in public issues of REITs, InvITs with effect from 1 August
- Netflix lays off 450 employees in two months—Here's what's bothering OTT giant
UK's Vectura wins patent infringement case against GlaxoSmithKline in U.S
British drugmaker Vectura Group Plc said on Saturday that it won a patent infringement litigation case against GlaxoSmithKline Plc in the United States and has been awarded $89.7 million in damages for the period from August 2016 through December 2018.
A jury trial in a Delaware district court on Friday found that one of Vectura`s U.S. patents was infringed by sales of three of GSK`s Ellipta products in the United States, Vectura said.
The jury found that GSK, which is also a UK-based pharmaceutical company, willfully infringed the patent, which Vectura said gives it the right to seek enhanced damages.
Vectura expects to seek application of the 3 percent royalty to sales of the infringing products through the end of the patent term in mid-2021, it said.
Vectura started legal proceedings against GSK in July 2016 after a patent license agreement between the two companies expired and GSK declined to license additional patent families under the original agreement.
GSK did not respond to Reuters request for comment outside regular business hours.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.